ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVGT Novagant Corporation (PK)

0.0045
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novagant Corporation (PK) USOTC:NVGT OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0045 0.0045 0.0067 0.00 14:30:22

Novagant, Inc. Enters Potential $8.4 Billion Medical Cannabis Industry With an All Legal Medical "Hemp" Cannabis Vaporizer

25/06/2014 2:30pm

Marketwired


Novagant (PK) (USOTC:NVGT)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Novagant (PK) Charts.
Novagant, Inc. Enters Potential $8.4 Billion Medical Cannabis Industry With an All Legal Medical "Hemp" Cannabis Vaporizer

DENVER, CO--(Marketwired - June 25, 2014) -  Novagant, Inc. (PINKSHEETS: NVGT) is pleased to announce its new medical cannabis vaporizer product, GLAVape™ (Generally Legal American Vape), which is the finest and most consistent Cannabidiol (CBD)-rich hemp oil in the world. 

Hemp is available over the counter (OTC) in all 50 States and over 40 Countries. It is not marijuana and does not require a medical marijuana license for purchase. Although both hemp and marijuana are in the same cannabis family of plants, they are vastly different from a legal perspective.

Cannabidiol is looked for its "potential as a treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders." (http://www.projectcbd.org/about/introducing-cbd/)

According to an IBISWorld report, and as reported by The Street, the medical marijuana industry is expected to grow 63% in 2014, and reach $8.4 Billion in revenues by 2019. (http://www.thestreet.com/video/12747902/medical-marijuana-industry-revenue-could-reach-84-billion.html) 

The Company's GLAVape™ is 100% natural and derived from the federally-legal industrial hemp plant. The Company's unique hemp cultivars, combined with its proprietary technologies, produce the highest quality CBD-rich hemp oil in the world.

GLAVape™ is lab tested multiple times during the manufacturing process, from seed to shelf. The Company tests for CBD content, other cannabinoid content, yeast/mold/fungus, and bacteria like E. coli to ensure safety and quality.

Other features of the GLAVape™ are:

  •  Natural Organic (non-synthetic), safe, legal product.
  • Non-psychoactive.
  • 10% CBD+ by volume.
  • Decarboxylated and filtered.
  • Made from Hemp Oil (Seed & Stalk).
  • Is from non-GMO industrial hemp grown without pesticides, herbicides, or chemical fertilizers.
  • Is stringently lab tested for quality.
  • Is fully insured and independently certified.

The GLAVape™ Pen is available in 0.3ml, 0.6ml, and 1.0ml and sizes. Wholesalers in need of bulk quantities of GLAVape™ can contact a representative from Novagant, Inc. for wholesales pricing.

About Novagant, Inc. Novagant, Inc. was incorporated in the state of Nevada on February 23, 1987 under the name of Kendrex Systems, Inc. The Company underwent several name changes, and ultimately on November 26, 2013 changed its name to Novagant, Inc. For more information about the Company, please visit www.novagant.com.

Safe Harbor: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact: Novagant, Inc. office@novagant.com

1 Year Novagant (PK) Chart

1 Year Novagant (PK) Chart

1 Month Novagant (PK) Chart

1 Month Novagant (PK) Chart

Your Recent History

Delayed Upgrade Clock